IL142982A0 - β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION - Google Patents

β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION

Info

Publication number
IL142982A0
IL142982A0 IL14298299A IL14298299A IL142982A0 IL 142982 A0 IL142982 A0 IL 142982A0 IL 14298299 A IL14298299 A IL 14298299A IL 14298299 A IL14298299 A IL 14298299A IL 142982 A0 IL142982 A0 IL 142982A0
Authority
IL
Israel
Prior art keywords
treatment
nucleosides
deoxy
hiv infection
acyl
Prior art date
Application number
IL14298299A
Other languages
English (en)
Original Assignee
Centre Nat Rech Scient
Univ Emory
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Emory, Uab Research Foundation filed Critical Centre Nat Rech Scient
Publication of IL142982A0 publication Critical patent/IL142982A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL14298299A 1998-11-05 1999-11-05 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION IL142982A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10717898P 1998-11-05 1998-11-05
US11586299P 1999-01-13 1999-01-13
PCT/US1999/026156 WO2000025799A1 (en) 1998-11-05 1999-11-05 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION

Publications (1)

Publication Number Publication Date
IL142982A0 true IL142982A0 (en) 2002-04-21

Family

ID=26804484

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14298299A IL142982A0 (en) 1998-11-05 1999-11-05 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION
IL142982A IL142982A (en) 1998-11-05 2001-05-04 Medicaments containing ?? - l-azido - 2',3' - dideoxy - 5 - fluorocytidine derivatives for the treatment of hiv infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142982A IL142982A (en) 1998-11-05 2001-05-04 Medicaments containing ?? - l-azido - 2',3' - dideoxy - 5 - fluorocytidine derivatives for the treatment of hiv infection

Country Status (12)

Country Link
EP (1) EP1124565B1 (enExample)
JP (2) JP2002528510A (enExample)
KR (1) KR100679239B1 (enExample)
AT (1) ATE321561T1 (enExample)
AU (1) AU768059B2 (enExample)
BR (1) BR9915037A (enExample)
CA (1) CA2348948C (enExample)
DE (1) DE69930678T2 (enExample)
ES (1) ES2262366T3 (enExample)
IL (2) IL142982A0 (enExample)
MX (1) MXPA01004505A (enExample)
WO (1) WO2000025799A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
BR9610120A (pt) * 1995-09-07 1999-12-21 Univ Georgia Res Found Composição farmacêutica e processo para aumentar a meia vida de um medicamento em um indivìduo e para melhorar uma condição patológica em um paciente.
SK284054B6 (sk) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
JP2002528510A (ja) 2002-09-03
AU768059B2 (en) 2003-12-04
AU1469100A (en) 2000-05-22
ES2262366T3 (es) 2006-11-16
KR100679239B1 (ko) 2007-02-07
KR20020013475A (ko) 2002-02-20
DE69930678T2 (de) 2006-09-21
DE69930678D1 (de) 2006-05-18
BR9915037A (pt) 2001-11-20
MXPA01004505A (es) 2005-04-19
JP2011251968A (ja) 2011-12-15
WO2000025799A1 (en) 2000-05-11
IL142982A (en) 2010-05-17
CA2348948A1 (en) 2000-05-11
CA2348948C (en) 2007-09-18
EP1124565A1 (en) 2001-08-22
EP1124565B1 (en) 2006-03-29
ATE321561T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
DK1104436T3 (da) Beta-L-2'-deoxy-nukleosider til behandling af hepatitis B-virus
IL142983A0 (en) Nucleosides with anti-hepatisis b virus activity
RU95110698A (ru) Способ лечения инфекций, вызываемых вирусом гепатита в
NZ330137A (en) L-nucleoside and L-nucleotide derivatives and their use in treating a human infected with HBV or EBV
WO2001079246A3 (en) 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
CA2215190A1 (en) Aryl-ester phosphoramidate derivatives of nucleosides
PT790974E (pt) Acidos 4-biarilbutiricos ou 5-biarilpentanoicos substituidos e seus derivados como inibidores de metaloproteinas de matriz
YU92102A (sh) Metode i smeše za lečenje virusnog hepatitisa c
ATE223424T1 (de) Quinazolinon-verbindungen
GR3034379T3 (en) L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents
WO1996006620A3 (en) Lipid analogs for treating viral infections
DK1165096T3 (da) Anvendelse af cytidinderivater til behandling af leukæmi
YU109289A (en) Process for obtaining anti-virus and anti-bacteria compound
NZ510811A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
DE69930678D1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv-infektionsbehandlung
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
IL93594A0 (en) Pharmaceutical compositions containing an imidazopyrimidone derivative
RU2001115094A (ru) Нуклеозиды, обладающие активностью против вируса гепатита в
CA2538205A1 (en) Nucleosides with anti-hepatitis b virus activity
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV